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HIGHLIGHTS 
The present ENMC workshop report summarizes recent clinical, molecular and genetic 
advances in the field of RYR1-related myopathies, and their current translation into clinical 
practice for patient benefit. 
 
1. Introduction and overview 
 
17 clinicians and basic scientists from 7 countries, as well as 4 patient representatives, 
gathered for the 217
th
 ENMC International Workshop on RYR1-related Myopathies from 29-
31
st
 January 2016 in Naarden, the Netherlands. The skeletal muscle ryanodine receptor 
(RYR1) gene encodes the principal sarcoplasmic reticulum (SR) calcium release channel 
(RyR1) with a crucial role in excitation-contraction coupling (ECC). Over the last decade, 
dominant and, more recently, recessive RYR1 mutations have emerged as the most common 
cause of non-dystrophic inherited neuromuscular disorders, including various congenital 
myopathies – Central Core Disease (CCD), Multi-minicore Disease (MmD) and 
Centronuclear Myopathy (CNM), Congenital Fibre Type Disproportion (CFTD) -, the 
Malignant Hyperthermia Susceptibility (MHS) trait and exertional rhabdomyolysis (ERM). 
The present workshop was the 5
th
 ENMC workshop solely dedicated to RYR1-related 
neuromuscular conditions, including previous ENMC workshops on CCD in January 2001 
[1], MmD in May 2000 [2] and November 2002 [3], and the various core and other RYR1-
related myopathies in March 2007 [4] and April 2011 [5], respectively.  
Following an introduction by Alexandra Breukel, Managing Director of the ENMC, on 
behalf of all co-organizers Heinz Jungbluth, (London, UK) summarized recent 
developments in the field of RYR1-related myopathies (RYR1-RMs), and outlined the major 
themes and objectives of the present workshop. Since the most recent ENMC workshop on 
RYR1-RMs in 2011, the phenotypical spectrum has expanded further, in particular in relation 
to RYR1 mutations associated with recessive inheritance, and induced or late myopathic 
manifestations of dominant RYR1 mutations previously mainly associated with the MHS trait. 
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In addition to advances in the understanding of the disturbances of intracellular Ca
2+
 
homeostasis and ECC underlying dominant RYR1 mutations, novel pathogenic mechanisms 
in particular underlying recessive RYR1-RMs are emerging. The first pharmacological 
compounds are currently being trialled based on these observations, and further clinical trials 
are likely to follow in the near future. As an important step towards the translation of research 
findings into patient benefit, the RYR-1 Foundation (www.ryr1.org) was recently established 
as a support and advocacy group for individuals affected by RYR1-related conditions and 
their families. Following the introduction by the organizers, Mike Goldberg and Jennifer 
Ryan from the RYR-1 Foundation (Pittsburgh, USA) provided a unique patient and family 
perspective on RYR1-RMs, and how their RYR-1 Foundation was established.  
 
2. Clinical spectrum of RYR1-related myopathies: genotype-phenotype correlations 
 
Heinz Jungbluth (London, UK) summarized novel, induced and late-onset myopathic 
phenotypes associated with dominant, mainly MHS-related RYR1 mutations. Malignant 
Hyperthermia (MH), a pharmacogenetic predisposition to adverse reactions in response to 
halogenated anaesthetics and muscle relaxants, and CCD were the first conditions to be 
attributed to defective RyR1 function. The clinical and mutational overlap between MH and 
myopathies such as CCD and the King-Denborough syndrome (KDS) [6] has been 
recognized for some time, but the recently observed consistent association of certain RYR1 
mutations with (exertional) rhabdomyolysis (ERM) [7, 8] suggest that ERM may be a more 
common manifestation of MH-related RYR1 mutations than actual MH itself. 
Rhabdomyolysis, sudden catastrophic muscle breakdown in response to various triggers, is 
commonly attributed to metabolic or other neuromuscular conditions but a substantial 
proportion of patients remain genetically unresolved despite extensive investigations. Recent 
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findings suggest that MH-related RYR1 mutations may account for between 20-30% of cases 
with ERM, often in individuals with above average athletic abilities but rarely a personal or 
family history of MH. Common triggers of RYR1-related ERM include exercise, increased 
environmental temperatures, alcohol, drugs  - or a combination of the above - but, in contrast 
to most metabolic causes, not fasting. A recently reported case of a fatal, RYR1-related MH 
reaction in the context of general anaesthesia administered shortly after unaccustomed intense 
exercise suggests that the latter may also play a role in MH pathogenesis [9]. RYR1-related 
rhabdomyolysis may also occur in the context of (viral) illness without additional triggers, 
mimicking viral myositis [7, 10]. Another recently recognized but probably less frequent 
manifestation of MH-related RYR1 mutations is late-onset axial myopathy [11, 12], 
characterized by progressive weakness of paravertebral muscles in previously normally 
strong (or even particularly muscular) individuals; despite a clear association with MH-
related RYR1 mutations, low penetrance and intrafamilial variability of this phenotype 
suggests the presence of additional (genetic) modifiers, as well as genetic heterogeneity. 
Lastly, periodic paralysis, previously reported in one isolated case [13], has now been 
observed in two other patients (unpublished findings) and is likely to be a rare but genuine 
association in a subset of RYR1 mutations. 
Carsten Bönnemann (Washington, USA) outlined early-onset RYR1-related phenotypes. 
The typical presentation of congenital CCD due to dominant RYR1 mutations is that of 
congenital hypotonia and weakness, possibly presenting with hip dislocation at birth. Motor 
milestones are delayed, but independent ambulation is eventually achieved. Weakness tends 
to be most prominent in the pelvic girdle and quadriceps, with little involvement of the face 
and normal extraocular movements. Motor abilities then show some improvement followed 
by a long period of stability, with possible progression later in adulthood. Severe neonatal 
presentations were first described in 2003 [14], due to autosomal recessive or dominant RYR1 
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mutations and occasionally associated with neonatal death. One severely affected dominant 
case had both cores and rods on muscle biopsy. Some severe patients with dominant RYR1 
mutations and central cores may survive the neonatal period but show severe motor 
involvement, sometimes precluding independent ambulation, and progressive severe early 
onset scoliosis, but without facial or extraocular involvement. The severely affected patients 
reported in Romero et al. (2003) in whom ventilation was continued showed motor 
improvement, eventually acquired some respiratory autonomy and, in one case, independent 
ambulation after 5 years of age (Ana Ferreiro, personal observation).  
Recessive RYR1 mutations have become increasingly recognized due to the ability to assess 
the entire RYR1 coding sequence beyond the known hotspots. Overall there is a tendency for 
earlier and more severe presentation compared to most patients with dominant mutations 
[15], however, it has become apparent that recessive RYR1 mutations are associated with a 
wide range of clinical phenotypes and pathological histotypes. A given phenotype may be 
associated with variable histotypes and vice versa; however, some more distinctive 
associations are emerging. A group of recessive RYR1 mutations may present with typical 
central core or with multi-minicore pathology, which may coexist in the same patient either 
in different muscles at the same time, or in temporal succession. The clinical phenotype 
ranges from severe neonatal and potentially lethal to later milder presentations, with similar 
distribution of weakness as seen as in typical dominant CCD, or sometimes including 
additional hand weakness. The pathological picture of RYR1-related centronuclear myopathy 
(CNM) [16] is characterized by internalized nuclei, sometimes centralized but often multiple 
per fiber, with unevennness of oxidative stains that can sometimes assume core or multi-
minicore like characteristics. Patients characteristically present with external 
ophthalmoparesis of variable degree, frequently associated with facial weakness.  A similar 
clinical presentation may also be associated with a more purely multi-minicore like histotype. 
Page 5 of 34
 6 
Patients have also been reported as presenting with a histopathological pattern more 
resembling CFTD, but still with external ophthalmoparesis [17]. In addition, there are 
patients presenting with considerable muscle weakness with a histotype more typical of a 
congenital muscular dystrophy (CMD) or other nonspecific histological manifestations, 
including striking fiber atrophy but without cores. Despite considerable skeletal muscle 
weakness in these patients the extraocular muscles are spared, and early progressive scoliosis 
is prominent. Thus, amongst the recessive RYR1-associated phenotypes there may be at least 
two clinical groups emerging – with and without ophthalmoparesis, with the former being 
associated with internal/central nucleation or a multi-minicore like pathology, while in the 
latter group the histotypes may be that of CCD or CMD and other nonspecific histologies. 
Going forward, an in depth analysis correlating genotypes with phenotypes, histotypes and 
most importantly pathophysiological consequences (physiotype) will be most helpful in 
elucidating these complex relationships. 
Caroline Sewry (London, UK) presented a summary of the main pathological features of 
muscle biopsies from patients with RYR1 mutations. She emphasised the heterogeneity of 
pathology and the limitations in our understanding of their meaning. In common with other 
congenital myopathies, necrosis is rarely a feature but the amount of adipose and connective 
tissue can be variable. In some very young cases these can be extensive, resembling a CMD, 
but it is unknown if these findings reflect loss of muscle tissue or failure of muscle fibres to 
form normally. Sampling may also be a factor as differential involvement of muscles is seen 
with muscle MRI [18, 19]. Internal nuclei and central nuclei are frequently a feature and 
some cases have been reported to pathologically resemble a CNM. These cases, however, do 
not often show the pale peripheral halo seen in MTM1-related XLMTM on oxidative enzyme 
stain. The cause and effect of mislocalised nuclei is not known but nuclear positioning can 
influence gene expression and be influenced by nuclear membrane proteins, microtubules and 
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the cytoskeleton. Fibre typing in RYR1-RMs often shows a uniform pattern or predominance 
of slow type 1 fibres. Fibre type disproportion without any additional defect may also occur 
but immunolabelling for myosin isoforms indicates that not all fibres with slow myosin are 
small and some may co-express fast myosin, indicating a need to re-evaluate fibre type 
disproportion in terms of myosin isoforms. The cause and effect of type 1 fibre predominance 
in congenital myopathies is not known, although innervation, the NFAT and calcineurin 
pathways are known to be involved. As fibre necrosis is rare, regenerating fibres are also not 
a feature but very small (“pinprick”) fibres (less than 5 microns) expressing fetal myosin can 
be seen, however, those are not specific to RYR1 myopathies. Cores with disrupted myofibrils 
and absent mitochondria are the best known feature associated with RYR1 defects but they 
can be variable in size or may even be absent. Large cores (single or multiple) running down 
an appreciable length of fibres are often associated with C-terminal dominantly inherited 
RYR1 mutations, whereas small, multiple cores are more often associated with recessively 
inherited RYR1 mutations but are not specific. Various proteins accumulate in core areas and 
in some fibres cores may show intense peripheral labelling of proteins such as desmin. It is 
then important to distinguish cores from target fibres. RYR1-related cases with exertional 
myalgia and malignant hyperthermia often show only mild, non-specific myopathic 
pathological features. 
Jim Dowling (Toronto, Canada) presented a summary of his published genotype-phenotype 
correlation study investigating recessive RYR1-related myopathies [20]. This study consisted 
of an analysis of 14 new and 92 published cases.  His team (in collaboration with the late 
Nigel Clarke, Sydney Australia) examined mutation type (missense versus hypomorphic) and 
location in reference to histopathologic subtype and clinical severity.  Overall, approximately 
50% of the 106 cases were non-core myopathies, with diagnoses including CNM, CFTD, and 
other non-specific histopathological findings. Patients with non-core myopathies were more 
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likely to have at least one hypomorphic mutation (i.e. a mutation that causes a partial loss of 
gene function), particularly as compared to recessive CCD.  Importantly, the presence of at 
least one hypomorphic allele was significantly associated with increased clinical severity, 
implying that reduced levels of the RyR1 protein result in more severe disease. In terms of 
mutation location, while mutations are present throughout the protein, there was an 
enrichment of missense mutations in the 3 previously described “hotspot” regions affecting 
the N-terminal, central and C-terminal domains, particularly in patients with core myopathies. 
Mutations located in hotspot 3 and the triadin binding domain were associated with a more 
severe clinical phenotype. Lastly, ophthalmoplegia was common across all subtypes, but 
more frequently seen with hypomorphic mutations.  One future direction based on this work 
will be to perform a more dedicated examination of missense mutations and see whether 
certain mutations are more highly associated with ophthalmoplegia. 
Heinz Jungbluth (London, UK) presented on RYR1 in the context of other congenital 
myopathies. Recent epidemiological studies covering different geographical areas have 
identified RYR1 mutations as the most common cause of congenital myopathies [21, 22]. 
Reflective of their overall frequency, different RYR1 mutations may be running 
independently in the same family [15], complicating genotype-phenotype correlations and 
genetic counselling, or may occur in addition to other monogenic conditions [23], 
emphasizing the importance of considering “double-trouble” in patients with RYR1-related 
myopathies and unexpected additional features. In particular recessive RYR1-related 
myopathies share marked clinico-pathological overlap with SEPN1-related myopathies and 
XLMTM, probably reflecting common defects in redox regulation and triad assembly, 
respectively. Other congenital myopathies that have to be considered in the differential 
diagnosis of recessive RYR1-related are those due to recessive mutations in the MYH2 gene 
[24] if extraocular muscle involvement is present, or in TTN [25] or MYH7  [26, 27] in the 
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presence of cardiac involvement. Recessive mutations in STAC3 are a recently identified 
cause of a KDS-like phenotype with recurrent MH episodes early in life [28].              
Nicol Voermans (Nijmegen, The Netherlands) presented the results of a retrospective cohort 
study investigating the clinical, genetic and histopathological features of all pediatric and 
adult patients referred to a national centre for both malignant hyperthermia and inherited 
myopathies over a 5 year period (2008-2012) in whom RYR1 mutations had been identified 
[29]. Among 277 patients tested, RYR1 mutations were detected in 77 non-related patients 
(detection rate 28%), featuring both congenital myopathies with permanent weakness and 
‘induced’ myopathies (“dynamic presentations”) such as MHS and non-anesthesia-related 
episodes of rhabdomyolysis or hyperCKemia, triggered by various stimuli. Sixty-one 
different RYR1 mutations were detected, of which 24 were novel. Some RYR1 mutations 
behaved as dominant with regards to the MHS but as recessive with regards to congenital 
myopathy phenotypes, even within the same family. Age of onset varied from birth to 60 
years in dominant and from birth to 10 years in recessive cases. Histopathological features 
included an equally wide spectrum, ranging from only subtle abnormalities such as increase 
of internal nuclei or unevenness of oxidative staining, to prominent cores. A series of three 
subsequent muscle biopsies in one patient showed the development of central cores over 
time. Some biopsies showed mild inflammatory or mitochondrial changes, obscuring the 
correct diagnosis. Since publication of the original paper, the Dutch cohort has now extended 
to 108 non-related patients.  
The ERM phenotype (see above) was prominent in the Dutch series and was illustrated in 
more detail in a separate report [8]. The first patient initially reported as 7.II.2 in Dlamini et 
al [[7]] and carrying the common European MH mutation Gly2434Arg, has so far suffered 
six episodes of rhabdomyolysis in response to different triggers, including exercise, stress and 
viral infections. Her brother, carrying the same mutation, has asymptomatic hyperCKemia 
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(up to 1200 IU/l) but no rhabdomyolysis history despite a strenuous exercise regime. The 
second patient, compound heterozygous for RYR1 mutations p.Val4849Ile and p.Ile2321Val, 
experienced recurrent rhabdomyolysis episodes after cycling (CK up to 28000 IU/l). His 
father, a carrier of the RYR1 p.Val4849Ile mutation was asymptomatic, but his uncle had 
suffered from exercise-induced myalgia for years; he also carried the p.Val4849Ile mutation 
and had a mildly myopathic muscle biopsy, suggesting large intrafamilial variability. Late 
onset axial myopathy (see above) [11, 12] was also prominent in the Dutch cohort, with four 
patients presenting between the third and sixth decade with predominant axial muscle 
involvement, comprising variable degrees of lumbar hyperlordosis, scapular winging and/or 
camptocormia; in one case, scapular winging was markedly asymmetric, mimicking 
facioscapulohumeral dystrophy (FSHD).  
Phil Hopkins (Leeds, UK) presented genotype-phenotype correlations in hyperthermic 
manifestations of RYR1-related myopathies. Hyperthermia is defined as an increase in body 
temperature in the presence of a normal central thermoregulatory set-point, and can result 
from abnormal heat gain, a failure of heat dissipation, or a combination of both. Life-
threatening hyperthermia is called heat stroke but clinical diagnosis of heat stroke requires an 
assessment of cerebral function. During general anaesthesia, it is not possible to clinically 
assess cerebral function and so the development of a progressive life-threatening 
hyperthermic reaction under anaesthesia requires an alternative name. This is why the 
classical hyperthermic manifestation of RYR1 myopathy, which occurs during general 
anaesthesia, is known as malignant hyperthermia (MH) and not heat stroke. Genotype-
phenotype relationships in MH-susceptible individuals can be explored using data obtained 
from the diagnostic in vitro muscle contracture tests. Results from such analyses show that 
the degree of in vitro muscle response depends on the specific RYR1 mutation carried by the 
patient. There is also evidence that gene dose affects the phenotype: For example, the RYR1 
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p.R3772Q mutation is associated with MH in the heterozygous state but in the homozygous 
state there is also a clinical myopathy. In a cohort of 62 individuals with a history of 
exertional heat illness and abnormal thermoregulation as determined by a standardised heat 
tolerance test, the Leeds team have identified nine individuals with rare and potentially 
pathogenic RYR1 variants.  Work is ongoing to determine the functional significance of these 
variants. Recent publications have re-awakened interest in the concept of a human stress 
syndrome with RYR1 aetiology. It must be emphasised that, by definition, these cannot be 
termed “awake” malignant hyperthermia reactions. The reported cases had features of muscle 
hypertrophy and the reactions were notable for early muscle rigidity often associated with a 
febrile or viral illness, observations that parallel the porcine stress syndrome (PSS). In 
contrast, in the typical human MH response under anaesthesia, muscle rigidity is a relatively 
late manifestation of the hypermetabolic and hyperthermic syndrome. 
 
3. RYR1 sequence variation and human disease 
 
Phil Hopkins (Leeds, UK) presented the analysis of RYR1 variants in the UK MH cohort. 
The latest European Malignant Hyperthermia Group (EMHG) diagnostic guidelines have 
introduced the option of primary DNA screening for the index case, a possibility largely 
arisen through the cost-effectiveness of next-generation sequencing (NGS) technology.  Even 
before the introduction of NGS, only a minority of the more than 200 MH-associated RYR1 
variants had been shown to produce a functionally relevant defect. Such functional studies are 
vital before variants can be used diagnostically because RYR1 is a genetically diverse gene in 
which rare, potentially pathogenic variants are found in up to 6% of control populations. The 
Leeds team have used NGS to sequence the entire RYR1 coding region in a cohort of 126 
unrelated UK MH families who had undergone a variable degree of previous genetic analysis. 
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RYR1 variants were found in 72 samples but only on 20 of these were the variants known to 
be pathogenic or likely to be pathogenic. Sixteen variants were known polymorphisms or 
unlikely to be pathogenic, while 50% of the RYR1 variants found were of unknown 
significance. 
Sheila Riazi (Toronto, Canada) presented on malignant hyperthermia (MH), exertional heat 
illness (EHI) and RYR1-related myopathies: distinct entities or a continuum? MH, a 
potentially fatal pharmacogenetic disease, is classically triggered by volatile anaesthetics. 
During an MH crisis the dysregulated rise of myoplasmic Ca
2+
 leads to hypermetabolism, 
through yet undefined pathways. Despite the reports showing a possible connection between 
EHI and MH, distinction between these entities is challenging, due to variations in clinical 
presentation, inconclusiveness of genetic testing, and the fact that caffeine halothane 
contracture test (CHCT) is not designed to diagnose EHI. However, it is vital to know if MH 
patients should be warned against exercise in heat, or if EHI patients should avoid volatile 
anaesthetics. In this proof of concept study, Dr Riazi and colleagues compared 
hypermetabolic details in anaesthetic induced and non-anaesthetic induced MH patients with 
controls, on the cellular level by exploring Ca2+ movements in muscle cells and through 
metabolomics, and on the clinical level by in vivo assessment of muscle metabolism using 
31
P-magnetic resonance spectroscopy. Applying such a multipronged approach, they showed 
that measurement of Ca2+ concentration and fluxes in conjunction with clinical information 
can be used to classify these patients more precisely. More specifically, metabolomics study 
showed impairments of both carbohydrate and fatty acid metabolism pathways in EHI but 
even more so in anaesthetic-induced MH patients. The markers of oxidative stress were 
significantly higher in MH and EHI, compared to controls. Finally, in vivo techniques of 
muscle tissue metabolism were indicative of impaired oxidative phosphorylation pathways 
both in MH and EHI patients. These preliminary results have established the feasibility and 
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accuracy of the applied approach. This project is the first step towards finding similarities and 
common target in these heterogeneous disorders. 
Susan Treves (Basel, Switzerland) presented recently reported findings concerning novel 
pathogenic mechanisms in recessive RYR1-RMs, obtained through a study to gain 
mechanistic insight into the causes of the reduced RyR1 content commonly observed in 
recessive RYR1-RMs. Muscle biopsies from patients with recessive RYR1 mutations were 
found to exhibit decreased expression of muscle specific microRNAs, increased DNA 
methylation of one of the CpG islands within the RYR1 gene, and increased expression of 
class II histone deacetylases; the latter event was accompanied by down-regulation of histone 
acetylation and by increased nuclear co-localization of HDAC-4 and mef-2. Transgenic 
mouse muscle fibres over-expressing HDAC-4/HDAC-5 for 1 week exhibited decreased 
expression of RYR1 and of muscle specific miRNAs, while acute knock-down of RYR1 in 
mouse muscle fibres by siRNA caused up-regulation of HDAC-4/HDAC-5. These results 
indicate that a pathophysiological pathway caused by epigenetic changes is activated in the 
muscles of some patients with recessive RYR1-RMs. Future investigation will be aimed at 
unravelling the mechanism by which RYR1 mutations activate this epigenetic pathological 
loop and verifying whether DNA methyltransferases and class II HDACs could be targeted 
pharmacologically to improve the muscle function in this group of patients. 
 
4. The basic science of RYR1-related myopathies 
 
Andy Marks (New York, USA) presented recent findings from his team concerning the 
crystal structure of mammalian ryanodine receptors and Rycals as a treatment option for 
RYR1-RMs. RyR channels are required for release of calcium from intracellular stores, a 
process essential for many cellular functions including excitation-contraction (EC) coupling 
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in skeletal and cardiac muscle, and hormone and neurotransmitter release. RyRs are amongst 
the largest ion channels, comprised of the four identical ~565 kDa channel-forming 
protomers, as well as regulatory subunits, enzymes and their respective targeting/anchoring 
proteins, in a macromolecular complex that exceeds three million Daltons. Andy Marks’ team 
have obtained high-resolution cryo-electron microscopy (Cryo-EM) reconstructions from 
highly purified rabbit skeletal muscle RyR1 in the open and closed states. These data reveal 
that RyRs are members of the six transmembrane family of ion channels and show a 
mechanism for channel gating that couples a change in the conformation of the Ca
2+
 binding 
site directly to opening of the channel pore, suggesting that Ca
2+
 binding facilitates 
mechanical coupling of conformational changes in the cytosolic region to opening of the 
channel gate. The channel-specific ligand ryanodine shows the channel to be locked in an 
open state consistent with the know effects of ryanodine on the single channel properties of 
RyR1. Their team have mapped >180 disease causing mutations on the structure proving 
insight regarding disease mechanisms for arrhythmias and muscular dystrophies. 
Unpublished clinical data on patients and RyR1 single channel studies have been conducted 
to better understand how mutations in the skeletal muscle RyR1 cause RYR1-RMs. This 
information may also yield insights as to which disease causing mutations are likely to 
respond to treatment with Rycals, a novel class of RyR stabilizing drugs, for guiding future 
clinical trials. Ca
2+
 leak through dysfunctional RyR1 may affect gene expression, protease 
activity, and redox homeostasis and has been linked to several myopathic conditions 
including Duchenne muscular dystrophy, sarcoglycanopathies, and sarcopenia. In these 
conditions secondary, post-translational modification of RyR1 causes pathologic Ca
2+ 
leak 
leading to myopathy. Stabilizing RyR1s with Rycals reduces Ca
2+ 
leak and improves muscle 
function in mice with these myopathies.  
The presentation from Robert Dirksen (Rochester, USA) started with a historical recount of 
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how analyses of RYR1 disease mutations have provided clues into important functional 
regions of the RyR1 Ca
2+
 release channel. For example, the discovery of the RYR1 I4898T 
mutation in a large Mexican family with CCD [30] quickly led to the identification of the 
selectivity filter of the RyR1 channel [31]. The I4898T mutation was subsequently shown to 
reduce RyR1 Ca
2+
 release by altering Ca
2+
 permeation (“EC uncoupling”) of the channel 
[32]. Similarly, functional studies of MH and CCD mutations in the N-terminal and central 
regions of RyR1 [33, 34] led to the idea that some disease mutations promote RyR1 Ca
2+
 
sensitivity to opening (“Ca2+ leak”) by disrupting critical inter-domain interactions important 
for stabilizing the channel closed state [35, 36]. The recent use of cryo-electron microscopy 
to obtain high resolution structures of RyR1 by three groups in early 2015 was a major 
breakthrough for the field as these structures provide unprecedented insight into the 
mechanisms by which RYR1 disease mutations alter RyR1 channel function [37-39]. Bob 
Dirksen presented unpublished collaborative biochemical and functional studies for specific 
MH- and CCD-related RYR1 mutations located in regions of the high resolution RyR1 
structure predicted to either promote channel activity by stabilizing the channel open state 
(Ca
2+
 leak) or reduce Ca
2+
 release by stabilizing the channel closed state (EC uncoupling). It 
is expected that the continued refinement of high resolution structures of the RyR1 open and 
closed states will provide additional important new insights into the pathophysiological 
mechanisms of RYR1-related disorders. 
Francesco Zorzato (Ferrara, Italy) presented results from a recent study describing altered 
calcium homeostasis in arterial smooth muscle cells (SMCs) in the MH Y522S mouse model 
(unpublished findings). Since RyR1 is expressed not only in skeletal muscle, RYR1 mutations 
may lead to alterations of Ca2+ homeostasis also in other tissues expressing this intracellular 
calcium release channel, even if at lower levels. Prompted by the clinical observation of an 
increased bleeding tendency in some patients with MH-related RYR1 mutations (see below), 
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biochemical characterization and immunofluorescence analysis of RyR1 in arterial smooth 
muscle cells were performed in the Y522S mouse model. Aorta and tail artery were found to 
express the RyR1 transcript, although, as expected, to a much lower extent than skeletal 
muscle. Tail artery smooth muscle cells isolated from the RYR1 Y522S knock-in mouse 
exhibited increased frequency of localized calcium release events (sparks) and smaller 
intracellular Ca2+ stores compared to WT littermates, although the resting calcium 
concentration was not affected.  Calcium sparks frequency was also found to be increased 
and associated with a more negative membrane potential in smooth muscle cells from 
RyRY522S mice compared to SMCs isolated from WT littermates. These findings 
demonstrate that MH-associated RYR1 mutations alter vascular smooth muscle cell function 
by affecting calcium homeostasis. 
 
5. Animal models and therapy development for RYR1-related myopathies 
 
Susan Hamilton (Houston, Texas) presented her work on therapy developments using mouse 
models of RYR1 myopathies. Mutations affecting the type I ryanodine receptor (RyR1) 
are associated with human muscle diseases including MH, MH with cores, CCD, MmD, and 
others. Some CCD mutations increase SR Ca 
2+
 leak, but others decrease Ca 
2+
 permeation 
through RyR1, raising the question of how mutations that lead to opposing functional effects 
on RyR1 can result in related disease phenotypes. Dr. Hamilton described the use of two 
mouse models of RYR1-RMs (Y522S and I4898T) to assess mechanisms of disease and 
develop new interventions. In particular, she discussed efficacy of AICAR [40], N-
acetylcysteine [41], and low dose rapamycin [42] for improving muscle function in these 
modes models. She also discussed recent findings with the I4898T mice (a RyR1 pore 
blocking mutation) and the need for very different approaches to improving muscle function 
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in these mice than those used with the Y522S mice with Ca 
2+
 leaky mutations. She discussed 
both progress toward developing drugs that improve muscle function in mice with RyR1 pore 
blocking mutations and the potential of CRISPR technology to eliminate or edit the mutated 
allele in these mouse models of dominantly inherited RYR1-RMs. The work with the mouse 
models suggest that, at least in mice, the RYR1-RMs are progressive and that different 
mutations reduce muscle function by different underlying mechanisms. These findings 
suggest the need for mutation-specific interventions. 
Ana Ferreiro (Paris, France) summarized and discussed the role of oxidative stress as a 
pathophysiological mechanism in RYR1-RMs and its relevance as a therapeutic target. She 
stressed the clinical and histological overlap between RYR1-RMs and myopathies associated 
with defects in SEPN1, encoding the putative antioxidant protein selenoprotein N, suggesting 
that common pathophysiological pathways, including defects in redox homeostasis, are 
involved in both conditions. The ryanodine receptors are exquisitely sensitive redox sensors, 
due to their exceptionally high content in cystein residues (404 per tetramere), which 
represent a large number of free thiols whose oxidation or nitrosylation influences channel 
function. Moreover, several sets of cystein thiols have differential susceptibility to redox 
modifications by PO2, nitric oxide, the ratio between reduced and oxidized glutathion 
(GSH/GSSG) or S-nitrosoglutathione (GSNO), which provides fine functional modulation of 
RyRs in response to different redox-related changes in the extracellular and intracellular 
environment. Excessive and continuous accumulation of reactive oxygen and nitrogen 
species can alter this physiological regulation, leading to RyR hypernitrosylation and, if 
unchecked by the antioxidant defence system, ultimately to oxidative muscle injury. Such 
mechanisms play an important role in physiological conditions such as fatigue after exercise 
[43] but also in RYR1-related skeletal muscle dysfunction. Thus, it has been demonstrated 
that oxidative stress (reduced GSH/GSSG) and redox remodeling of RyR1 (increased RyR S-
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glutathionylation and nitrosylation) cause calcium leak in vitro and mitochondrial injury in 
RYR1-MH mutant mice [41]. In addition, collaborative research between the groups of Ana 
Ferreiro and Jim Dowling established that oxidative stress is involved also in RYR1-RMs 
[44]. The total level of reactive oxygen species, mainly of mitochondrial origin, and of 
carbonylated/oxidated proteins is increased both in myotubes from RYR1-mutated patients 
and in the ryr zebrafish. Treatment with the antioxidant N-acetylcysteine (NAC) reduced 
oxidative stress markers and improved survival in oxidant conditions in RYR1-mutated 
myotubes, ameliorated aspects of the ryr motor phenotype and reduced the ultrastructural 
abnormalities (ER dilatation, minicores) in muscles from the zebrafish model [44]. These 
studies established that oxidative/nitrosative stress is a relevant and targetable 
pathomechanism in RYR1-RMs, and that NAC is an effective ex vivo and in vivo treatment in 
relevant animal models, thereby laying the basis for current clinical trials and for future 
therapeutic approaches. Ana Ferreiro discussed the need for additional studies to establish the 
correlation between the type of RYR1 mutation and its redox-related functional consequences, 
in order to identify biomarkers and outcomes useful for future personalized therapeutic 
approaches.  
Jim Dowling (Toronto, Canada) discussed small animal models of RYR1-related myopathies 
and their application for drug discovery. He briefly presented the relatively relaxed (ryr) 
zebrafish model, which has a insertion/frameshift mutation in ryr1b, and was used for 
discovering N-acetylcysteine as a potential therapy for patients with RYR1-RMs [44]. He then 
introduced the unc68 nematode model, a C. elegans mutant strain with a loss of function 
mutation in ryr.  He described a sensitized drug screen using this model, and presented the 
preliminary results of a large-scale screen that he (with collaborator Peter Roy, University of 
Toronto) recently performed.  He concluded by describing several new mutants, both in C. 
elegans and in zebrafish, that his laboratory is in the process of generating.  These new 
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mutants will more accurately model human RYR1-related myopathies by having engineered 
point mutations that have been described in patients with different subtypes of disease.   
Julien Fauré from the team of Isabelle Marty (Grenoble, France) presented genomic 
medicine approaches to RYR1 therapeutics. RYR1-related pathologies are heterogeneous in 
their presentation and genetic bases. Although promising molecular tools are being developed 
for in vivo DNA editing, several barriers have to be removed to reach clinical trial readiness 
for these techniques. Conversely, RNA-based therapies are already tested in phase III clinical 
trials and could provide a promising therapeutic approach. The team from Grenoble has 
studied a pathological situation in which an affected child harbors two recessive RYR1 
mutations, resulting in a massive RyR1 reduction, and has developed an exon-skipping 
strategy with a modified U7-AON to block the effect of the paternally inherited mutation 
(which induces the inclusion of a new in frame exon in the RYR1 mRNA, resulting in the 
insertion of additional amino acids and destabilization of the protein) in affected primary 
muscle cells. Expression of the U7-AON in primary patient muscle culture resulted in 
reduced inclusion of the additional exon, an increase in RyR1 protein expression, and 
restoration of normal calcium releases. This study is the first demonstration of the potential of 
exon skipping for a recessive RYR1-RM. Further steps required to reach clinical trial 
readiness were presented and discussed. 
Francesco Muntoni (London, UK) reported data on targeting dominant RYR1 mutations 
using gapmer oligonucleotides, specifically designed to target alleles carrying the mutations 
and induce RNase-H mediated RNA cleavage. The strategy followed in collaboration with Dr 
Haiyan Zhou in the London laboratory consists in targeting common single nucleotide 
polymorphisms (SNPs) in linkage disequilibrium with the mutant allele. If the targeting of the 
SNP is successful, this should theoretically leave the wild type allele intact, providing a 
potentially interesting approach for dominant RYR1-RMs. Proof of concept has been obtained 
Page 19 of 34
 20 
so far in an immortalized myoblast cell line derived from a patient carrying a dominant 
mutation in RYR1 exon 91, with RNA sequencing clearly indicating the possibility to achieve 
allele specific silencing using the gapmers.  
 
6. Non-skeletal muscle presentations of RYR1-related myopathies 
 
In addition to striated skeletal muscle, RyR1 receptors are expressed in a range of other 
tissues but non-neuromuscular manifestations associated with mutations in RYR1 have so far 
not been reported. Heinz Jungbluth (London, UK) and Nicol Voermans (Nijmegen, 
Holland) presented non-neuromuscular manifestations (including bleeding abnormalities, 
smooth muscle, CNS and cardiac involvement) seen in their cohorts of RYR1 mutated 
patients in the United Kingdom and the Netherlands.  
Heinz Jungbluth presented evidence for a novel, RYR1-associated bleeding abnormality. 
Assessment of bleeding abnormalities through a standardized bleeding questionnaire 
(MCMDM-1VWD) demonstrated an increased bleeding tendency in patients carrying RYR1 
gain-of-function mutations compared to normal controls (unpublished findings). The 
observed bleeding phenotype was more pronounced in RYR1-mutated females, characterized 
by severe menorrhagia and post-partum hemorrhage, and often associated with other signs of 
smooth muscle involvement affecting bowel and bladder. Corresponding to findings in RYR1-
mutated humans, bleeding times in the MHS RYR1Y522S knock in mice exhibited 3 times 
longer bleeding times compared to their wild type littermates, probably reflecting impaired 
SMC involvement in these animals (collaborative work with Susan Treves and Francesco 
Zorzato, see above). Most importantly, the bleeding phenotype could be complete reversed 
by administration of the RyR1 antagonist Dantrolene, suggesting Dantrolene as a therapeutic 
option for RYR1-related and potentially other bleeding disorders.     
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Other recently observed non-neuromuscular manifestations of RYR1 mutations include severe 
CNS involvement in an adolescent suffering a fatal MH episode [9]; the pattern of prominent 
cerebellar involvement seen in this patient showed striking similarities with 
neuropathological changes described in deceased heat stroke victims [45]. An intriguing 
potential link between RYR1-related ERM and the Neuroleptic Malignant Syndrome (NMS) 
is indicated by the implication of certain psychopharmacological drugs such as Olanzapine as 
triggering agents in individuals with ERM and confirmed pathogenic RYR1 mutations [7].       
Nicol Voermans presented evidence for cardiac involvement in the Dutch cohort of patients 
with RYR1-RMs. In four unrelated patients within this cohort, the family history revealed 
sudden death at a relatively early age in one or more family members. Post-mortem studies 
were not performed in any of the deceased individuals, and the sudden death was considered 
to be of cardiac origin. There were no symptoms suggestive of a non-anaesthetic MH 
reaction. These patients included the brother of a patient with a late-onset axial myopathy due 
to the RYR1 p.Val4849Ile mutation who died suddenly at the end of running a marathon. 
Other cardiac features in the same series included dilated cardiomyopathy presumed to result 
from a viral infection, bicuspid aortic valve, and sinus bradycardia. The cause of these 
observations is unclear, as the main cardiac isoform in the heart is RYR2 and cardiac RYR1 
expression is limited. Smooth muscle cell involvement in arteries and arterioles (see above) 
could be a possible explanation. A possible cardiac phenotype associated with RYR1-RMs 
ought to be investigated further.  
 
7. Clinical trials in RYR1-related myopathies 
 
Francesco Muntoni (London, UK) presented data on the challenges to clinical trials for rare 
neuromuscular diseases. He remarked that so far only single centre limited data exist on the 
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natural history of RYR1-RMs, and that outcome measures for these conditions have not been 
widely characterised. There are no large international registries, but a collection of smaller 
national ones; and there are no biomarkers that have been validated and that could be used as 
surrogate markers to monitor disease progression and response to therapy. All these are 
bottlenecks to trial readiness. In other neuromuscular disorders, for example several forms of 
muscular dystrophies and spinal muscular atrophy, significant resources have been 
concentrated in registries and longitudinal multicentre collection of core clinical data from 
the relevant patient population; on studies of biomarkers; and on testing of outcome measures 
in a multicentre setting. These are very helpful steps in facilitating at a later stage the 
involvement of industrial partners, as the lack of the above deter from considering this an 
area worth exploring for therapeutic developments 
Katy Meilleur (Washington, USA) reported on the currently ongoing clinical trial of N-
acetylcysteine (NAC) in RYR1-RMs in the USA.  In preclinical models of RYR1-RMs, 
including mice, zebrafish and patient myotubes, treatment with NAC, an FDA approved drug 
for various indications, has shown decreased oxidative stress plus increased muscle force [41] 
and increased swim endurance [44]. Additionally, numerous human trials of NAC in healthy 
and other diseased populations have shown decreased oxidative stress [46, 47] and decreased 
time to fatigue [48]. Given the disabling nature of congenital myopathy symptoms, the 
limited side effect profile of orally administered NAC, and the lack of any FDA approved 
treatment for these conditions, the benefit of performing a clinical trial in individuals with 
RYR1-RMs outweighs the risk. However, lack of validated clinical outcome measures and 
biomarkers in this population pose a barrier to clinical trial readiness. Thus, a two-phase 
study including an initial natural history/outcome measure validation phase followed by a 
randomized, double-blind, placebo controlled phase is being conducted. Subjects are seen at 
baseline, 6 months, and 12 months. All outcome measures are performed off-drug at the first 
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two visits. At the end of the second visit, patients start drug or placebo for the following 6 
months and return at 12 months to perform all outcome measures on intervention. Primary 
outcome measures, chosen based on work in preclinical models, include plasma glutathione 
(GSH:GSSG) by mass spectrometry for oxidative stress (Specific Aim 1) and 6 Minute Walk 
Test (6MWT) for endurance (Specific Aim 2). Additionally, several secondary and 
exploratory outcomes are performed for each specific aim with the goal of validation against 
the primary outcome measures, which serve as gold standards. So far, 32 participants have 
been enrolled in the study, including 17 adults, and 15 children. The majority of participants 
(n=23, 72%) have CCD (n=21, 66%) or MmD (n=2, 6%), or other RYR1-RM phenotypes 
(n=9, 28%). Results based on analysis of the first 32 participants indicate that regarding Aim 
1, baseline values for GSH:GSSG are significantly decreased (13.2+5.8) compared to 
reported healthy controls (21.3+10.3; p<0.05), suggesting this endogenous antioxidant is 
depleted in RYR1-RM due to mitochondrial oxidative stress, as seen in the 3 preclinical 
models. Adults and children in the current study did not show a significant difference in 
GSH:GSSG. Regarding Aim 2, participants analysed so far had a total mean distance on the 
6MWT of 479m (±132m), with adults averaging 481m (±127m) and children averaging 
476m (±142). 8 subjects (5 adults and 3 children) reached > 95% predicted distance. Several 
secondary and exploratory measures for oxidative stress and endurance showed preliminary 
correlations with their respective gold standard measure. Results showing significant 
depletion of GSH:GSSG are encouraging as they confirm findings in preclinical models and 
allow for the potential of NAC to replenish these levels. For more mildly affected 
participants, the 6MWT reaches a ceiling effect. If necessary, the ceiling effect of the 6MWT 
may be overcome by analyzing inter-individual differences, as planned in the original study 
design, and/or by performing a subgroup analysis of more affected individuals who achieve 
less than 80-90% predicted distance. 
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Ana Ferreiro (Paris, France)  presented the clinical trial using NAC to treat SEPN1-related 
myopathies (SEPN1-RM) (SELNAC) which is currently in progress in France 
(ClinicalTrials.gov Identifier:NCT02505087). Based on the identification by her group of 
oxidative stress as a relevant pathophysiological mechanism, and of cystein-donors and 
particularly NAC as an effective treatment ex vivo in SEPN1-RM, a preclinical study was 
conducted using the SEPN1 KO mouse model. This study demonstrated improvement of 
several muscle function parameters upon treatment with moderate NAC dosages, and led to 
the identification of systemic biochemical changes that represent potentially useful 
biomarkers (Dill et al., in preparation). These parameters will be used to monitor and quantify 
response to treatment in the SELNAC trial, which is a phase II-III, randomized, double blind, 
placebo-controlled, cross-over study on 24 French adult patients. Detailed motor and 
respiratory function parameters will also be quantified before and after treatment. The 
possibility of extension of this or similar studies to the paediatric SEPN1-RM population 
were discussed. Furthermore, Dr. Ferreiro presented data about clinical trial readiness in the 
French RYR1-RM population, including over 100 patients.  
 
8. Conclusions, outcomes and deliverables from the workshop 
 
Although a number of relatively large retrospective single centre series have already been 
published, large prospective multicentre data concerning the natural history of RYR1-RM are 
still lacking and pose a considerable obstacle for trial readiness. Moreover, reflecting the 
immense clinical heterogeneity of RYR1-RM, there is no single assessment tool with the 
ability to robustly collect information from profoundly weak to ambulant patients, resulting 
in the need to adapt already existing tools and to define suitable functional outcome measures 
for these widely heterogeneous conditions. There is also a need to determine additional 
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biomarkers for RYR1-RM, both concerning monitoring of general disease progression (for 
example through serial muscle MRI) but also with regards to pathways targeted by specific 
drugs (for example in plasma or on muscle biopsies). One deliverable of the workshop was 
therefore to establish a consortium specifically dedicated to a multicentre natural history 
study and definition of biomarkers and outcome measures. A first objective of this 
consortium will be to examine more precisely potential genotype correlations for example 
with ophthalmoparesis, a study designed to both unify existing patient cohorts and to serve as 
a springboard for future genotype-phenotype correlation studies. 
In addition to pharmacological compounds already being trialled such as acetylcysteine, the 
need to consider clinical trials for compounds currently being investigated at the pre-clinical 
stages (for example, Rycals and AICAR [40]) or previously tested in small pilot studies or 
single cases only (for example, Salbutamol [49] and Dantrolene [7, 8]) was discussed.    
Another recurrent theme throughout the workshop was the considerable challenge of 
correctly assigning pathogenicity to the large numbers of RYR1 variants currently being 
identified due to recent advances in genetic diagnostics, and the lack of a central repository 
for the collection of reliable genotype-phenotype data. To assess pathogenicity more reliably, 
collaborations between clinicians and basic scientists were established at the workshop, to 
pursue a more in depth study of selected RYR1 variants through combined analysis of clinico-
pathological, functional and crystallographic data. Already existing genotype-phenotype 
databases were discussed and further enquiries will be made as to the most suitable currently 
existing databases for adaptation as a RYR1 genotype-phenotype repository. Another 
deliverable of the workshop in relation to this topic is to partner with an existing NIH-led 
effort (Dr Les Biesecker, Bethesda, USA) to develop algorithms for assessing RYR1 variants.     
Another important question identified at the workshop is the uncertainty regarding the 
malignant hyperthermia (MH) risk potentially associated with the large number of novel, in 
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particular recessive RYR1 mutations currently being identified; the anaesthetists and 
clinicians present at the workshop agreed to produce a joint position paper to provide 
practical guidance on this complex issue. In addition to the potentially increased MH risk, an 
increased bleeding tendency, sudden unexplained death and a substantial disease burden 
through pain and fatigue were identified as potentially important disease associations that will 
warrant more systematic study through a validated questionnaire approach.  
Lastly, patient representatives present at the workshop emphasized the importance of wider 
awareness of standards of diagnostics and care concerning RYR1-RM and other congenital 
myopathies, and this will be achieved through wider dissemination of two recent international 
consortia papers [50, 51] covering these topics.  There was also discussion of enhancing 
awareness of and participation of patient registries, and particularly the registry established 
by the RYR1-Foundation, as well as working toward development (in part through the 
registry) of a global natural history study. 
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